BIOADAPTIVES INC
For the period ended Dec 31, 2023. Filed Apr 10, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 10, 2024
BDPTStored price and day change unavailable
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
| Years ended | ||
|---|---|---|
| December 31, | ||
| 2023 | 2022 | |
| Revenues | $28,565 | $17,176 |
| Cost of revenue | 17,746 | 10,050 |
| Gross Profit | 10,819 | 7,126 |
| Operating Expenses | ||
| General and administrative | 101,478 | 254,119 |
| Professional fees | 110,088 | 112,759 |
| Amortization of license and patent | 28,174 | 62,148 |
| Total Operating Expenses | 239,740 | 429,026 |
| Loss from operations | (228,921) | (421,900) |
| Other Income (Expense) | ||
| Unrealized gain (loss) on marketable securities | (42) | (148) |
| Interest expense | (162,891) | (289,121) |
| Change in fair value of derivative liabilities | (307,412) | (184,401) |
| Loss on settlement of debt | (13,200) | - |
| Total Other Expense | (483,545) | (473,670) |
| Loss before income taxes | (712,466) | (895,570) |
| Net Loss | $(712,466) | $(895,570) |
| Net Loss Per Common Share: | ||
| Basic and Diluted | $(0.00) | $(0.01) |
| Weighted Average Number of Common Shares Outstanding: | ||
| Basic and Diluted | 559,069,032 | 106,011,449 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.